Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Australia to buy extra 20 million doses of Pfizer vaccine

Australia says it has finalized a deal to buy an extra 20 million doses of the Pfizer vaccine as it rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca vaccine

Via AP news wire
Friday 09 April 2021 05:53 BST
Virus Outbreak Australia Vaccine
Virus Outbreak Australia Vaccine

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Australia said Friday that it has finalized a deal to buy an extra 20 million doses of the Pfizer vaccine as it rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca vaccine.

Prime Minister Scott Morrison announced the deal just hours after saying Australia would stop using the AstraZeneca vaccine for people aged under 50.

He said the deal means Australia will get a total of 40 million doses of the Pfizer vaccine by the end of the year, enough to inoculate 20 million people in the nation of 26 million.

Australia's pivot came after the European Medicines Agency said this week it had found a “possible link” between the AstraZeneca vaccine and rare blood clots, though regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people.

After the European agency's declaration, Australian drug regulators held a series of urgent meetings Thursday and recommended the Pfizer vaccine become the preferred vaccine for people under 50.

Morrison said there was no prohibition on the AstraZeneca vaccine and the risk of side effects was remote. He said the change was being made out of an abundance of caution.

The pivot represents a significant shift in Australia's overall approach and is likely to delay plans to have everybody inoculated by October.

A major part of Australia’s strategy had been the ability to make its own vaccines at home and not rely on shipments from abroad. It had planned to manufacture some 50 million doses of the AstraZeneca vaccine, enough for 25 million people. Australia had made no plans to make any other vaccines at home.

Even before the change, the government was facing criticism for a rollout program that's lagging behind those in most other developed nations. So far, Australia has administered just over 1 million vaccine doses.

Opposition Leader Anthony Albanese said the rollout was a debacle and Australians needed certainty about when they would be vaccinated.

“This government has failed. This government couldn’t run a choko vine up a back fence,” Albanese told reporters, referring to a plant that produces pear-shaped fruit and grows easily in the Australian climate.

Health Minister Greg Hunt said there would be some adjustments but everybody would be kept safe and would get vaccinated.

Australia has managed to stamp out community spread of the virus, allowing life to continue much as before the pandemic.

AstraZeneca noted Australia’s decision to restrict the vaccine's use was based on it having no community transmission.

“Overall, regulatory agencies have reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks,” the company said in a statement.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in